Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).

Article Details

Citation

Copy to clipboard

Silverman LR

Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS).

Oncologist. 2001;6 Suppl 5:8-14.

PubMed ID

11700387 [ View in PubMed

]

Abstract

Considerable progress has been made recently in defining and understanding the diverse members of the group of hematologic disorders now known as the myelodysplastic syndrome (MDS). New systems of classification, based on the latest cytogenetic methodologies, have generated better prognostic data, and basic research has more closely associated molecular mechanisms with clinical subgroups. The mechanisms underlying most cases of myelodysplasia appear to be an array of chromosomal abnormalities leading to suppression of normal myeloid cell differentiation and dominance of abnormal, immature cells. The process is progressive and is mediated by a variety of cytokines, potential loss of tumor suppressor genes, aberrations in signal transduction pathways, and perhaps immune mechanisms. Hypermethylation of specific DNA sequences has been implicated in the pathogenesis of MDS. Until recently, treatment options have been few, high risk, and mostly ineffective. New discoveries, particularly in the area of stimulating remaining normal myeloid cells to resume growth and differentiation, hold promise for safer treatment regimens and improved outcomes. Among the promising new agents are nucleoside analogues, such as 5-azacytidine and decitabine, which reactivate tumor suppressor gene transcription through effects on DNA methylation.

DrugBank Data that Cites this Article

Drugs

Azacitidine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Azacitidine	DNA (cytosine-5)-methyltransferase 1	Protein	Humans	Yes	Inhibitor	Details